China Daily | Simcere eyes growing pharmaceutical niche

Envafolimab Granted FDA Orphan Drug Designation for Gastric and GEJ Cancer

SIM0610, Simcere Zaiming's a Bispecific Antibody-Drug Conjugate Approved for Clinical Trials

Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

Simcere Zaiming Announces Inclusion of Enzeshu^® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List

Simcere Donates HKD 5 Million to Support Hong Kong Fire Rescue Efforts

Simcere Enters Exclusive Licensing Collaboration with Vigonvita for New Indications of Deuterium Hydrobromide Remididevir Against RSV Infection

Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

SIM0609 Doses First Patient in Phase I Clinical Study at Peking University Cancer Hospital